Early combination therapy is typically recommended for those with T2D and an HbA1c level of 7.5% or higher, often involving metformin and either a glucagon-like peptide-1 (GLP-1) receptor agonist, SGLT-2 inhibitor, or DPP-4 inhibitor. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.